Rauwolscine

Rauwolscine is a yohimbine stereoisomer and indole alkaloid derived from plants such as Rauwolfia serpentina and Pausinystalia yohimbe, acting primarily as an alpha-2 adrenergic receptor antagonist. By blocking alpha-2 receptors, it may promote catecholamine-driven lipolysis and reduce appetite, though robust human clinical evidence remains limited.

Origin & History

Rauwolscine is a naturally occurring indole alkaloid primarily extracted from the bark of Rauwolfia serpentina (Indian snakeroot) and related species. It is the 3-epi stereoisomer of yohimbine and can be produced through traditional solvent extraction from plant bark or modern yeast-based microbial fermentation methods.

Historical & Cultural Context

While rauwolscine occurs naturally in Rauwolfia plants used in traditional Ayurvedic medicine, no specific historical or traditional uses of isolated rauwolscine are documented in the available research. The compound has been studied primarily as an isolated bioactive rather than in ethnopharmacological contexts.

Health Benefits

• May support weight management through reduced food intake (preliminary evidence from animal studies showing 3-6 hour appetite suppression in mice, PMID: 6145164)
• Potential metabolic effects through alpha-2 adrenergic receptor antagonism (preclinical evidence only)
• May influence serotonin signaling via 5-HT receptor interactions (in vitro binding studies only)
• Possible cardiovascular effects through adrenergic modulation (limited to animal model data)
• Note: All benefits are based on preclinical research with no human clinical trials available

How It Works

Rauwolscine competitively antagonizes alpha-2 adrenergic receptors, which normally suppress norepinephrine release and inhibit lipolysis in adipose tissue; blocking these receptors elevates circulating catecholamines and enhances triglyceride breakdown via hormone-sensitive lipase activation. It also exhibits agonist activity at 5-HT1A and 5-HT2B serotonin receptors, contributing to its appetite-modulating and mood-influencing effects. Additionally, rauwolscine has demonstrated affinity for dopamine D3 receptors and imidazoline receptors, though the functional significance of these interactions in humans has not been well characterized.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses on rauwolscine were identified in the available research. All evidence comes from preclinical studies including receptor binding assays, animal models (pithed rats, mice), and in vitro experiments examining alpha-2 adrenergic and serotonin receptor interactions.

Clinical Summary

The most frequently cited evidence for rauwolscine's appetite-suppressive effects comes from rodent studies, including a 1984 mouse model (PMID: 6145164) showing a 3–6 hour reduction in food intake following acute administration. No large-scale randomized controlled trials in humans have been published specifically on isolated rauwolscine, making it difficult to extrapolate animal data to clinical outcomes. Most human research on alpha-2 antagonism in the context of fat loss has been conducted with the closely related compound yohimbine, which shares the same core mechanism; a double-blind crossover trial (n=20) found yohimbine increased fat oxidation by approximately 15% during exercise, suggesting a plausible parallel effect. Overall, the evidence base for rauwolscine in humans is preliminary and underpowered, and independent replication is necessary before efficacy claims can be substantiated.

Nutritional Profile

Rauwolscine (alpha-yohimbine) is a single indole alkaloid compound (C₂₁H₂₆N₂O₃, MW 354.44 g/mol), not a nutritional food source, and therefore does not possess a traditional macronutrient or micronutrient profile (no carbohydrates, fats, protein, fiber, vitamins, or minerals). It is a diastereomer (stereoisomer) of yohimbine, naturally occurring in the bark of Rauvolfia serpentina (Indian snakeroot) and Pausinystalia yohimbe at concentrations typically ranging from 0.01–0.5% of total alkaloid content in raw bark (substantially lower than yohimbine itself). Key bioactive properties: potent alpha-2 adrenergic receptor antagonist (Ki ≈ 1.3–5 nM at α2-adrenoceptors), with notable affinity for serotonin receptors including 5-HT1A (Ki ≈ 70 nM), 5-HT2A (Ki ≈ 40–100 nM), and 5-HT2B receptors. It also shows moderate affinity at dopamine D2 receptors. In commercial supplements marketed for fat loss, rauwolscine is typically dosed at 1–3 mg per serving, often standardized from Rauvolfia vomitoria or Pausinystalia yohimbe bark extracts. Bioavailability data in humans is extremely limited; however, as a lipophilic alkaloid it is expected to have reasonable oral absorption similar to yohimbine (oral bioavailability of yohimbine is ~22% due to significant first-pass hepatic metabolism). Rauwolscine is presumed to undergo hepatic CYP-mediated metabolism (likely CYP3A4 and CYP2D6 pathways by analogy with yohimbine). Half-life estimates in humans are not well-established but are speculated at approximately 2–5 hours based on structural similarity to yohimbine (t½ ≈ 0.5–2.5 hours). No established Recommended Daily Intake or Tolerable Upper Intake Level exists. The compound contains no caloric value and no essential nutrients.

Preparation & Dosage

No clinically studied dosage ranges for rauwolscine in humans are available. Preclinical studies used micromolar concentrations for in vitro assays but provide no guidance for human supplementation. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Yohimbine, caffeine, green tea extract, synephrine, L-tyrosine

Safety & Interactions

Rauwolscine may cause dose-dependent side effects including elevated heart rate, increased blood pressure, anxiety, insomnia, and gastrointestinal distress, mirroring the adrenergic stimulation profile of yohimbine. It carries a significant interaction risk with monoamine oxidase inhibitors (MAOIs), antihypertensive agents, stimulants such as caffeine or DMAA, and any norepinephrine reuptake inhibitors, as combined use can precipitate hypertensive crises or dangerous cardiovascular events. Rauwolscine is contraindicated in individuals with anxiety disorders, cardiac arrhythmias, hypertension, kidney disease, or a history of psychiatric illness. Pregnancy and breastfeeding safety has not been established, and use should be avoided in these populations; individuals should consult a physician before use, particularly those on prescription medications.